OTC Generics Firm PFI Needs To Address Possible System Failures – FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA is concerned that Pharmaceutical Formulations' corrective action plan in response to violations found during a GMP inspection does not address possible system failures in the firm's manufacturing practices